Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (0.6), the stock would be worth $0.21 (471% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.1 | $0.04 |
0%
|
| 3-Year Average | 0.6 | $0.21 |
+471%
|
| 5-Year Average | 0.6 | $0.21 |
+471%
|
| Industry Average | 0 | $0 |
-91%
|
| Country Average | 0 | $0 |
-91%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
2.6m USD | 0.1 | -0.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 0 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 9.5 | 86.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 7.4 | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 7.4 | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 769.8 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 9.6 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 4.1 | 16.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 11.6 | 36.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 26 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 6.4 | 29.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 664.3 |
Other Multiples
Adaptimmune Therapeutics PLC
Glance View
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. The company is headquartered in Abingdon, Oxfordshire and currently employs 494 full-time employees. The company went IPO on 2015-05-06. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.
